Table 1 Baseline demographics of overall prostate cancer patients and comparison between TPL and non-TPL groups

Age (years; mean, STD)

48.10 (10.24)

48.1 ± 10.24

48.1 ± 10.24

Age, 20 ≤ Age < 50

25,856 (49.84)

19,392 (49.84)

6464 (49.84)

 50 ≤ Age < 65

24,308 (93.41)

18,231 (93.41)

6077 (93.41)

 65 ≤ Age ≤ 75

1,688 (6.49)

1266 (6.49)

422 (6.49)

 75 < Age

28 (0.11)

21 (0.11)

7 (0.11)

Diagnostic Year of Prostate Cancer

 < .001

 2007–2009

1 (0.53)

0 (0)

1 (1.3)

 2010–2012

40 (21.28)

20 (18.02)

20 (25.97)

 2013–2015

147 (78.19)

91 (81.98)

56 (72.73)

Year of transplanted surgery

1.000

 2003–2007

12,524 (24.14)

9393 (24.14)

3131 (24.14)

 2008–2012

18,532 (35.72)

13,899 (35.72)

4633 (35.72)

 2013–2015

20,824 (40.14)

15,618 (40.14)

5206 (40.14)

Underlying disease

 Hypertension

15,511 (29.90)

7376 (18.96)

8135 (62.72)

 Diabetes

9,504 (18.32)

3253 (8.36)

6251 (48.2)

 Dyslipidemia

8,546 (16.47)

4461 (11.46)

4085 (31.5)

Medication

 Aspirin

1776 (3.42)

803 (2.06)

973 (7.5)

 Statin

8701 (16.77)

4389 (11.28)

4312 (33.25)

 Use of Immunosuppressant agents

21,578 (41.59)

8623 (22.16)

12,955 (99.88)

 Duration of immunosuppressant, ≥ 300 days

11,338 (21.9)

225 (0.6%)

11,113 (85.68)

Transplanted organ

 1. Kidney

7,026 (13.54)

N.A

7026 (54.17)

 2. Liver

5,445 (10.50)

N.A

5445 (41.98)

 3. Pancreas

28 (0.05)

N.A

28 (0.22)

 4. Heart

398 (0.77)

N.A

398 (3.07)

 5. Lung

73 (0.14)

N.A

73 (0.56)

Charlson Comordity Index Grade 2

 < 0.001

 0

23,693 (45.67)

23,689 (60.88)

4 (0.03)

 1

8,231 (15.87)

8126 (20.88)

105 (0.81)

 2 or more

19,956 (38.47)

7095 (18.23)

12,861 (99.16)

 Survival, alive

50,199 (96.61)

38,092 (97.90)

12,027 (92.73)

 Survival time (year; mean SD)

4.86 (2.49)

4.9 ± 2.49

4.73 ± 2.49